European Study Highlights Laserscope's Greenlight PV(R) System Effective in Relieving BPH Symptoms With Improved Safety and Lowe
January 10 2006 - 4:05PM
PR Newswire (US)
SAN JOSE, Calif., Jan. 10 /PRNewswire-FirstCall/ -- Laserscope
(NASDAQ:LSCP), a pioneer in the development and commercialization
of minimally-invasive medical devices, including medical lasers and
advanced fiber-optic delivery devices, today announced the positive
results of the first prospective study comparing Photoselective
Vaporization of the Prostate (PVP) performed with the Company's
GreenLight PV(R) laser system with the more traditional
Transurethral Resection of the Prostate (TURP) for the treatment of
obstructive Benign Prostatic Hyperplasia (BPH). Investigators from
the University of Basel and from Cantons Spital Baden in
Switzerland reported their findings in the December issue of the
European Urology journal. The authors of the study, which included
data from 101 patients, found that "PVP provides excellent
intraoperative safety, instant tissue removal, and immediate relief
from obstructive voiding symptoms, similar to TURP." Dr. Alexander
Bachmann, the study's lead investigator, commented that, "PVP has
become the standard of care at the University of Basel." Professor
Tullio Sulser, Head of the Urology Department at the University of
Basel, and senior author of the study added that, "The GreenLight
PV(R) laser system has proven to be an extremely effective tool in
our long-term experience of more then three years." The authors
also noted that PVP has the potential to reduce health care
expenses for the treatment of obstructive BPH. "Although capital
investment for the laser generator and disposable costs for the
single-use laser fiber are significant, cost savings for insurers
become evident once the shorter hospital stay, lower incidence and
reduced severity of post-operative complications for PVP compared
to TURP are taken into consideration." "We are very excited to see
published evidence of the significant advantages our GreenLight
PV(R) laser system offers over TURP, which has been the 'Gold
Standard' for the treatment of BPH over the last several decades,"
said Eric Reuter, President and Chief Executive Officer of
Laserscope. "Although long-term, follow-up of comparison trials are
still needed to confirm the initial positive results of this study,
we are convinced that PVP is becoming the new de-facto standard of
care given the growing number of consistently positive reports from
educational and medical centers around the world." About Laserscope
Laserscope designs, manufactures, sells and services on a worldwide
basis an advanced line of minimally-invasive medical products
including medical laser systems and related energy delivery devices
for the office, outpatient surgical center, and hospital markets.
More information about Laserscope can be found on the Company's web
site at http://www.laserscope.com/. Safe Harbor Statement This
press release contains forward-looking information within the
meaning of Section 21E of the Securities Exchange Act of 1934, and
is subject to the safe harbor created by this section. These
forward-looking statements include statements about the efficiency
of Laserscope's PVP procedure compared to transurethral resection
of the prostate in treating Benign Prostatic Hyperplasia. These
statements are subject to a number of risks and uncertainties,
including among others: uncertainties regarding introduction of new
technologies competitive to Laserscope's products and the degree to
which the Company's current and new products are accepted by
customers, which could affect the level of demand for our products;
uncertainties regarding our ability to compete with companies that
have significantly greater financial, technical, research and
development, manufacturing and marketing resources than we have;
and uncertainties that new products will receive regulatory
approval in applicable jurisdictions. Actual results may differ
materially due to these and other factors. The matters discussed in
this press release also involve risks and uncertainties described
from time to time in Laserscope's filings with the Securities and
Exchange Commission. In particular, see the Risk Factors described
in Laserscope's most recent Quarterly Report on Form 10-Q and
Annual Report on Form 10-K. Copies of Laserscope's public
disclosure filings with the SEC, including the most recent Annual
Report on Form 10-K and the most recent forms 10-Q are available
upon request from its Investor Relations Department at its website
at http://www.laserscope.com/ and at the SEC's website:
http://www.sec.gov/. Laserscope assumes no obligation to update the
forward-looking information contained in this press release. At
Laserscope: At Financial Relations Board: Eric Reuter, President
& CEO Tricia Ross, Investor/Analyst Contact Derek Bertocci, CFO
(617) 520-7064 (408) 943-0636 Laurie Berman, General Inquiries
(310) 854-8315 DATASOURCE: Laserscope CONTACT: Eric Reuter,
President & CEO, or Derek Bertocci, CFO, both of Laserscope,
+1-408-943-0636; or Investor/Analyst Contact, Tricia Ross,
+1-617-520-7064, or General Inquiries, Laurie Berman,
+1-310-854-8315, both of Financial Relations Board for Laserscope
Web site: http://www.laserscope.com/
Copyright
Laserscope (NASDAQ:LSCP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Laserscope (NASDAQ:LSCP)
Historical Stock Chart
From Jul 2023 to Jul 2024